Belite Bio, Inc (BLTE) income statement
BLTENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 5/30
$156.23−1.49 (-0.94%)
Close on Nov 18, 2026Market cap $6.15BP/E –Yield –
Belite Bio, Inc income statement
Ratios
Latest available, balances at Dec 31, 2025
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -16.9%
Financial strength
- Current ratio
- 50.02
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 3571.5%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 7.98
- Dividend yield
- –
See a number that looks wrong?